Senior finance professional with over 20 years of biotech/pharmaceutical corporate finance, commercial, and equity research / investment banking experience focused on:Finance & Corporate Strategy: Led executive teams and Boards in developing long range plans, annual operating plans, investment prioritization, defense plans, and capital strategy to maximize the value of Preclinical to Phase 3 oncology companies Raising Capital: Completed $6.1 billion in IPO, secondary, early stage (seed to Series B), and debt financings, including four S-1 filings, three S-3 filings and numerous private placements. M&A: Completed valuation analysis and due diligence for the sale of Fusion Pharmaceuticals to Astra Zeneca, multiple development-stage asset acquisitions and advised Othrofix International on the acquisition of Breg. Portfolio Prioritization: Established portfolio review committees and partnered with R&D leadership to establish development, technical, and commercial criteria to prioritize the development of over 65 preclinical and clinical stage heme-oncology, solid tumor and radiopharmaceutical assets and indicationsFinance & Accounting Operations: Built and managed teams responsible for FP&A, accounting, financial operations, internal controls, and ERP/financial systems implementation, and managed annual operating plans with $100 million to $1.9 billion in annual expensesCollaborations: Due diligence, negotiation, and integration of 7 major R&D out-licensing collaborations with large pharmaceutical partners covering 40 development stage programs, and 7 in-licensing transactions for 11 early stage programs from pre-IPO partnersCommercialization: Finance lead for the global commercial launch of 4 oncology products in 7 indications, and pre-commercial planning for over 20 development stage assetsIR & Investment Research: Authored over 6,000 pages of equity research reports, formulated investment recommendations on 36 companies, and developed IR strategy and presentations